Ivonescimab Achieves High Pathological Complete Response in Lung Cancer Trial

A Phase II clinical trial for ivonescimab in resectable non-small cell lung cancer (NSCLC) reported a 50.7% pathological complete response (pCR) rate. This was observed in patients receiving neoadjuvant ivonescimab plus chemotherapy who proceeded to surgery. This outcome surpasses pCR rates seen with current treatments, with 12-month event-free survival exceeding 80%, indicating a promising development for NSCLC patients.